synaptic vesicle glycoprotein 2A | Atypical major facilitator superfamily (MSF) proteins | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

synaptic vesicle glycoprotein 2A

Target id: 2634

Nomenclature: synaptic vesicle glycoprotein 2A

Family: Atypical major facilitator superfamily (MSF) proteins

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: OFF :     Currently no data for synaptic vesicle glycoprotein 2A in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 742 1q21.2 SV2A synaptic vesicle glycoprotein 2A
Mouse - 742 3 F2 Sv2a synaptic vesicle glycoprotein 2 a
Rat - 742 2q34 Sv2a synaptic vesicle glycoprotein 2a
Previous and Unofficial Names
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
levetiracetam Rn Inhibition 5.8 pKi 3
pKi 5.8 (Ki 1.58x10-6 M) [3]
brivaracetam Rn Inhibition 7.0 pIC50 1
pIC50 7.0 (IC50 1x10-7 M) [1]
Description: In vitro inhibitory activity against [3H](2S)-2-[4-(3-azidophenyl)-2-oxopyrrolidin-1-yl]butanamide binding to levetiracetam binding site, in rat brain homogenate.
levetiracetam Rn Inhibition 6.1 pIC50 1
pIC50 6.1 (IC50 7.94x10-7 M) [1]
Description: In vitro inhibitory activity against [3H](2S)-2-[4-(3-azidophenyl)-2-oxopyrrolidin-1-yl]butanamide binding to levetiracetam binding site, in rat brain homogenate
Clinically-Relevant Mutations and Pathophysiology
Disease:  Epilepsy
References:  2,4-5


Show »

1. Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV, Gillard MR et al.. (2004) Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J. Med. Chem., 47 (3): 530-49. [PMID:14736235]

2. Mendoza-Torreblanca JG, Vanoye-Carlo A, Phillips-Farfán BV, Carmona-Aparicio L, Gómez-Lira G. (2013) Synaptic vesicle protein 2A: basic facts and role in synaptic function. Eur. J. Neurosci., 38 (11): 3529-39. [PMID:24102679]

3. Noyer M, Gillard M, Matagne A, Hénichart JP, Wülfert E. (1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol., 286 (2): 137-46. [PMID:8605950]

4. Vogl C, Tanifuji S, Danis B, Daniels V, Foerch P, Wolff C, Whalley BJ, Mochida S, Stephens GJ. (2015) Synaptic vesicle glycoprotein 2A modulates vesicular release and calcium channel function at peripheral sympathetic synapses. Eur. J. Neurosci., 41 (4): 398-409. [PMID:25484265]

5. von Rosenstiel P. (2007) Brivaracetam (UCB 34714). Neurotherapeutics, 4 (1): 84-7. [PMID:17199019]

How to cite this page

Atypical major facilitator superfamily (MSF) proteins: synaptic vesicle glycoprotein 2A. Last modified on 22/02/2016. Accessed on 13/12/2018. IUPHAR/BPS Guide to PHARMACOLOGY,